Jan Kroon
YOU?
Author Swipe
The Impact of System Sizing and Water Temperature on the Thermal Characteristics of Floating Photovoltaic Systems Open
Accurately calculating the annual yield of floating PV (FPV) systems necessitates incorporating appropriate FPV-specific heat loss coefficients into the calculation, including both wind-dependent and wind-independent factors. The thermal b…
Modeled and Measured Operating Temperatures of Floating PV Modules: A Comparison Open
The power output of a photovoltaic system is dependent on the operating temperature of the solar cells. For floating PV (FPV), increased wind speeds can result in increased yield due to lowered operating temperatures, which has long been s…
Table S1 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Table S1
Figure S4 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A,B) Measurement of cell proliferation by [3H]thymidine incorporation (A) or WST assay (B) after treatment with increasing concentrations of RU-486 for 6 d (data represent mean + SE from at least 3 independent experiments (***, p< 0.001).
Figure S3 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Analysis of 3D-spheroid growth after GR knockdown with 1µg/ml doxycycline for 8 d in PC3, DU145, CWR22Rv1, LAPC4, and DUCaP cells (data represent Box Whisker Plots with 10-90 percentile from 3 independent experiments; ***, p< 0.001).
Figure S2 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) GR knockdown confirmation by Western blot analysis using 2 specific doxycycline inducible shGR-RNA sequences (shGR-1 and shGR-2) after activation with 1 µg/ml doxycycline for 6 d in DUCaP.
Table S1 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Table S1
Figure S5 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Screening for PR mRNA (left) and protein (right) expression in multiple breast and prostate cancer cell lines including positive (MCF7, T47D) and negative controls (MDA MB231, BT20).
Figure S9 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) Western blot analysis of GR and AR protein expression in different passages of long-term vehicle-ctrl treated LNCaPabl cells before and during (>10 mo) cultivation in the presence of EtOH.
Figure S11 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) GR and AR protein expression in abl sub-lines after inhibition of GR or AR expression and activity using 40 nM siGR/AR for 2 d and 12 µM RU-486/4 µM enzalutamide for 1 d prior to 8 h dexamethasone (1 µM) treatment.
Suppl Figure legends from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Suppl Figure legends
Figure S6 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) Proliferation and spheroid formation in DUCaP cells after 8 d of RU-486 treatment. Proliferation was assessed by ([3H]thymidine incorporation) after 6 d treatment with 10 µM RU-486.
Figure S1 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A, B) GR antibody specificity test in DU145 cells using 40 nM scrambled siRNA (siCtrl), 40 nM ON-TARGETplus GR siRNA (siGR), and 1 µg pCMV6-XL5 GR overexpression plasmid for 72 h by (A) Western blot and (B) IHC.
Figure S11 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) GR and AR protein expression in abl sub-lines after inhibition of GR or AR expression and activity using 40 nM siGR/AR for 2 d and 12 µM RU-486/4 µM enzalutamide for 1 d prior to 8 h dexamethasone (1 µM) treatment.
Figure S7 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) Representative pictures of parental and long-term abiraterone treated LNCaPabl, DUCaP, and LAPC4 cells.
Figure S10 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Analysis of GR mRNA and protein expression in long-term enzalutamide treated LNCaPabl, DUCaP, LAPC4, and LNCaP cells was performed by qRT-PCR and Western blot, respectively.
Figure S5 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Screening for PR mRNA (left) and protein (right) expression in multiple breast and prostate cancer cell lines including positive (MCF7, T47D) and negative controls (MDA MB231, BT20).
Figure S4 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A,B) Measurement of cell proliferation by [3H]thymidine incorporation (A) or WST assay (B) after treatment with increasing concentrations of RU-486 for 6 d (data represent mean + SE from at least 3 independent experiments (***, p< 0.001).
Suppl Figure legends from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Suppl Figure legends
Figure S9 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) Western blot analysis of GR and AR protein expression in different passages of long-term vehicle-ctrl treated LNCaPabl cells before and during (>10 mo) cultivation in the presence of EtOH.
Figure S7 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) Representative pictures of parental and long-term abiraterone treated LNCaPabl, DUCaP, and LAPC4 cells.
Figure S8 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Analysis of GR/AR mRNA and protein expression in long-term abiraterone treated LNCaPabl, DUCaP, and LAPC4 after (>10 mo) of cultivation in the presence of abiraterone or vehicle-ctrl (EtOH) was performed by qRT-PCR and Western blot, respec…
Figure S10 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Analysis of GR mRNA and protein expression in long-term enzalutamide treated LNCaPabl, DUCaP, LAPC4, and LNCaP cells was performed by qRT-PCR and Western blot, respectively.
Figure S2 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) GR knockdown confirmation by Western blot analysis using 2 specific doxycycline inducible shGR-RNA sequences (shGR-1 and shGR-2) after activation with 1 µg/ml doxycycline for 6 d in DUCaP.
Figure S1 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A, B) GR antibody specificity test in DU145 cells using 40 nM scrambled siRNA (siCtrl), 40 nM ON-TARGETplus GR siRNA (siGR), and 1 µg pCMV6-XL5 GR overexpression plasmid for 72 h by (A) Western blot and (B) IHC.
Figure S3 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Analysis of 3D-spheroid growth after GR knockdown with 1µg/ml doxycycline for 8 d in PC3, DU145, CWR22Rv1, LAPC4, and DUCaP cells (data represent Box Whisker Plots with 10-90 percentile from 3 independent experiments; ***, p< 0.001).
Data from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Purpose: The major obstacle in the management of advanced prostate cancer is the occurrence of resistance to endocrine therapy. Although the androgen receptor (AR) has been linked to therapy failure, the underlying escape mechanisms have n…
Figure S6 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
(A) Proliferation and spheroid formation in DUCaP cells after 8 d of RU-486 treatment. Proliferation was assessed by ([3H]thymidine incorporation) after 6 d treatment with 10 µM RU-486.
Data from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy Open
Purpose: The major obstacle in the management of advanced prostate cancer is the occurrence of resistance to endocrine therapy. Although the androgen receptor (AR) has been linked to therapy failure, the underlying escape mechanisms have n…